Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients  by Jahromi, Soodeh Razeghi et al.
Seizure 20 (2011) 343–346Short communication
Gastrointestinal adverse effects of antiepileptic drugs in intractable
epileptic patients
Soodeh Razeghi Jahromi a, Mansoureh Togha a,b, Sohrab Hashemi Fesharaki a, Masoumeh Najaﬁ a,
Nahid Beladi Moghadamc, Jalil Arab Kheradmand a, Hadi Kazemi a,e, Ali Gorji d,*
a Shefa Neuroscience Research Center, Tehran, Iran
b Iranian Center of Neurological Disease, Tehran, Iran
cBeheshti University of Medical Sciences, Emam Hossein Hospital, Tehran, Iran
d Institute fu¨r Physiologie I, Westfalische Wilhelms-Universita¨t Mu¨nster, Mu¨nster Universita¨t, Robert-Koch Str. 27a, D-48149, Mu¨nster, Germany
eDepartment of Pediatric, Shahed University, Tehran, Iran
A R T I C L E I N F O
Article history:
Received 22 March 2010
Received in revised form 3 December 2010
Accepted 14 December 2010
Key words:
Seizure
Pharmacotherapy
Refractory epilepsy
Clinical study
A B S T R A C T
Gastrointestinal (GI) discomforts are among the most common side effects of antiepileptic drugs (AEDs)
that might lead to discontinuation or irregular consumption of the drugs. This study was conducted to
evaluate the frequency of GI side effects of different AEDs in intractable epileptic patients treated with
single or multiple drugs. GI discomfort of 100 epileptic patients (aged 35–76 years) treated with one or
multiple AEDs was assessed. Seventy six patients (76%) were treated with two or more AEDs, and 24
(24%) were on monotherapy. The most common prescribed drug for monotherapy was carbamazepine
and the most frequent combination was phenytoin and carbamazepine. Patients were suffering from
different GI side effects including heartburn (34.6%), nausea (33.7%), constipation (26%), vomiting
(22.1%), diarrhea (21.2%) and dysphagia (19.2%). Nausea and vomiting were signiﬁcantly higher in
patients receiving monotherapy with carbamazepine and valproic acid, respectively. When phenytoin,
gabapentine, or valproic acid was added to the other AEDs, the risk of the occurrence of diarrhea,
dysphagia, or heartburn was signiﬁcantly increased, respectively. Addition of gabapentine to the other
AEDs in multiple drug therapy was accompanied with the highest frequency of GI complications. This
study indicated that GI side effects, which can affect drug absorption and utilization, were common in
intractable epileptic patients with long-term AEDs treatment. This may inﬂuence the efﬁcacy of the
therapy with AEDs and enhance the probability of further attacks.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Antiepileptic drugs (AEDs) are among the most commonly
prescribed centrally active agents1 not only for treatment of
epilepsy but in patients suffering from different types of pain as
well as psychiatric disorders. All classical AEDs including
carbamazepine (CBZ), phenobarbital (PB), oxcarbazepine (OXC),
phenytoin (PHT), valproate (VPA), and primidone (PRM) were
reported to be accompanied with various gastrointestinal (GI) side
effects including heartburn, nausea, constipation, vomiting, diar-
rhea, etc.2–4 Although new AEDs such as levetiracetam (LEV) and
topiramate (TOP) are accompanied with lower incidence of side
effects, they still have been reported to cause some GI distur-
bance.3,5 GI complications inﬂuence the AEDs absorption and
subsequently reduced the drug efﬁcacy. In addition, GI discomfort
may lead to irregular consumption of the AEDs.6 Therefore,* Corresponding author. Tel.: +49 251 8355564; fax: +49 251 8355551.
E-mail address: gorjial@uni-muenster.de (A. Gorji).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.011choosing proper single or combination AEDs therapy with less GI
effects is of great importance in epileptic patients, especially those
with drug-resistant attacks.
This study was conducted to assess the GI side effects of long-
term AEDs therapy in a group of patients with intractable post-
traumatic epilepsy. These patients were receiving either classical
and/or new AEDs in form ofmono ormultiple therapies. This study
may be helpful to recognize GI complications of each drug alone
and in combination with other medications in refractory epileptic
patients.
2. Patients and methods
GI complications were studied in 100 epileptic patients with
post-traumatic intractable epilepsy who referred to the Epilepsy
Clinic of Khatam-Alanbia Hospital in Tehran between January and
April 2009. These patients were all veterans with cranial injury
during Iraq–Iran war (1980–1988). Four neurologists assessed the
patients’ eligibility to enter the study. The participants who hadvier Ltd. All rights reserved.
Table 1
Diagnostic criteria for gastrointestinal discomforts.
Diarrhea More than three loose stool in a day for more than two consecutive days of most of the weeks
Constipation Abnormal stool form (at least 25% lumpy or hard stools), abnormal stool passage (at least 25% defecations
with straining and feeling of incomplete evacuation, manual maneuvers to facilitate more than 25% defecations)
and/or abnormal stool frequency (less than 3 bowel movements per week)
Vomiting Episodes of vomiting for at least three separate days in a week, in the absence of eating
disorders, rumination, and major psychiatric disorders in accordance with DSM-IV, self induction of vomiting, as well as
metabolic disturbances that can explain vomiting
Dysphagia Material may split from the mouth. Increase in the secretion of phlegm. Biting the tongue. Experiencing difﬁculty in
the beginning of the swallow. Sticking of food in a mouth. Choking or coughing during eating or drinking with or
without regurgitation of food. Meals are taking much longer time. Liquid or food coming through the nose.
Drinking extra ﬂuids with meal to wash food down.
Nausea Queasy, sick to the stomach discomfort that may progress to the sense of a need to vomit
Heartburn (pyrosis) Burning retrosternal sensation that can move up and down the chest like a wave. In more severe cases it may radiate
to the sides of the chest, the neck, and even the angles of the jaw18
Table 2
Characteristics features of epileptic attacks in 100 patients suffering from
intractable traumatic epilepsy. Data are presented as mean SEM. AEDs; antiepi-
leptic drugs.
Characteristics of the patients Number (%)
Seizure type
Tonic–clonic seizures 34 (34%)
Multifocal complex partial seizure 21 (21%)
Focal simple partial seizure 34 (34%)
Partial seizures evolving to secondarily generalized seizures 11 (11%)
Age (year) 42.98.26
Age at onset of seizures 25.26.83
Time interval between brain trauma and onset of seizures (year) 1.440.28
Seizure frequency (attacks per month) 32.73
Seizure duration (year) 18.037.1
Duration of AEDs therapy 17.326.3
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drugs would not be recruited. The basic characteristics (age, age of
seizure onset, duration of AEDs therapy, the interval between brain
trauma and seizure onset, seizure type, frequency and duration)
were obtained. GI discomforts were assessed according to the
diagnostic criteria which are summarized in Table 1. Prescribed
daily doses (PDDs) of AEDs (N03A ATC group) were recorded for
drugs used in monotherapy or in combination therapy. The PDD is
the average daily amount of the drug that is actually prescribed by
a speciﬁed group of physicians for a given time period. PDDs were
compared with the deﬁned daily doses (DDDs) suggested by WHO
in the ATC/DDD index.
The study was approved by the Ethic Committee of Shefa
Neuroscience Center and informed consent was obtained from
each patients.
Statistical values were presented as percent or mean  SD.
Because of the exploratory character of this study,when analyzing the
responses to the side effects checklist, we dichotomized complaints
as not present or present. Data were analyzed using SPSS, with
standard parametric (descriptive) statistics. For testing the differ-Table 3
Gastrointestinal side effects of antiepileptic drugs (AEDs) in patients treated with a sin
GI disorders AEDs
Carbamazepine
(9 patients)
Phenobarbital
(3 patients)
Pheny
(3 pat
Nausea 8 (72.2%)*,§ 2 (50%) 1(33.3
Vomiting 4 (36.4%) 2 (50%) 0
Dysphagia 5 (45.5%) 1 (25%) 1(33.3
Constipation 3 (27.3%) 1 (25%) 2(66.7
Heartburn 7 (63.6%) 3 (75%) 1(33.3
Diarrhea 4 (36.4%) 2 (50%) 1(33.3
§ Number (percent).
* P<0.05.ences between the several drugs non-parametric analysis of variance
was used, based on the Kruskal Wallis test. In addition correlational
analysis was performed to reveal the relation between PDDs and GI
complications, using Spearman test. Signiﬁcance was established
when the probability values were less than 0.05.
3. Results
Themean age of participants was 42.9  8.26 years (ranged: 35–
76). These patientswere treated for intractable epilepsy for 17.2  5.6
years. The characteristic features of seizure attacks in these patients
are shown in Table 2. Seventy six patients (76%) were treated with
two or more AEDs and 24 (24%) patients were on monotherapy. AEDs
included gabapentine (GBP), lamotrigine (LTG), OXC, TOP, VPA, PB,
PHT, and CBZ. The most common prescribed drug for monotherapy
was CBZ (9.6%) and the most frequent combination therapies were
PHT and CBZ (14.5%), PB and PHT (9.6%), as well as PB, PHT, and VPA
(5.8%; Table 4).
CBZ (41.7%) had the highest GI adverse effects in patients
treated with single drug. This follows by VPA (20.8%), PB (12.5%),
PHT (8.3%), and TOP (4.2%). GI adverse effects were at highest rate
when GBP (39%) was included in the combination-therapy. CBZ
(26.3%), PB (6.6%), PHT (3.9%), LTG (3.9%), VPA (1.3%), and OXC
(1.3%) were also associated with GI side effects in patients
receiving multiple AEDs for treatment of their epileptic attacks.
Themost commonGI complications observed either withmono
or multiple AEDs therapy were heartburn (35%), nausea (33%),
constipation (27.3%), vomiting (23%), diarrhea (22.2%), and
dysphagia (20%).
Nausea was signiﬁcantly higher in monotherapy with CBZ
(p = 0.026) as well as vomiting in monotherapy with VPA
(p = 0.047; Table 3). PHT (p = 0.02) and CBZ (p = 0.042) in
combination with other AEDs had signiﬁcant correlation with
occurrence of heartburn. In addition, administration of GBP and
VPA in combination with the other antiepileptic medications
signiﬁcantly increased the occurrence of diarrhea (p = 0.007) andgle drug.
toin
ients)
Valproate
(5 patients)
Gabapantine
(3 patients)
Topiramate
(1 patient)
%) 3 (50%) 0 0
4 (66.7%)* 1 (25%) 0
%) 2(33.3%) 0 0
%) 2(33.3%) 1(25%) 1
%) 2(33.3%) 0(0%) 0
%) 2(33.3%) 0 0
Table 4
Gastrointestinal side effects of antiepileptic drugs (AEDs) in patients treated with multiple drugs.
GI disorders AEDs
Carbamazepine Phenobarbital Phenytoin Valproate Lamotrigine Oxcarbazepine Gabapantine Topiramate
Nausea 15 (31.2%)§ 11 (23.4%) 11 (26.8%) 7 (31.8%) 3 (27.3%) 0 3 (42.9%) 1 (16.1%)
Vomiting 9 (18.8%) 7 (14.9%) 7 (17.1%) 4 (18.2%) 1 (9.1%) 1 (25%) 2 (28.6%) 0
Dysphagia 8 (16.7%) 7 (14.9%) 4 (9.8%) 3 (13.6%) 1 (9.1%) 0 3 (42.9%)* 1 (16.1%)
Constipation 15 (31.2%) 10 (21.3%) 11 (26.8%) 2 (9.1%)* 3 (27.3%) 2 (50%) 3 (42.9%) 2 (33.3%)
Heartburn 17 (35.4%)* 18 (38.4%)* 10 (24.4%) 11 (50%)* 3 (27.3%) 2 (50%) 0 1 (16.1%)
Diarrhea 9 (18.8%) 8 (17%) 3 (7.3%)* 2 (9.1%) 2(18.2%) 0 2 (28.6%) 1 (16.1%)
§ Number (percent).
* P<0.05.
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complications including nausea, vomiting, dysphagia, constipa-
tion, and diarrhea in patients on polytherapy has been observed
when GBP was included.
Mean PDDs (in mg) in mono-/combination-therapy in these
patientswere as follows (DDDs inmg; in parenthesis): CBZ 600 and
800 (1.0), PHT 300 and 400 (0.3), GBP 0.6 and 1.2 (1,800), LTG 200
and 350 (0.3), PB 100 and 150 (0.1), VPA 1 and 1.2 (1.5). The
assumed average maintenance daily dose of CBZ in monotherapy
was signiﬁcantly correlated to nausea (p = 0.002). The average drug
load of PHTwas also signiﬁcantly correlated to diarrhea in patients
treated by multiple AEDs (p = 0.03). After changing of AEDs, GI
adverse effects in abovementioned patients resolved.
4. Discussion
This study revealed that GI adverse effects are common in
patients suffering from intractable epilepsy and treated with
different AEDs for several years. In our investigation, patients
treated with GBP and CBZ tended to have the highest rate of GI
problems. GBP and CBZ were followed by VPA, and PB. An analysis
on Italy antiepileptic drug therapy showed a different toxicity
proﬁle related to each AED with common GI complications. This
study reported a high rate of GI adverse reactions correlated to GBP
(21%), LTG (13%), OXC (12%), CBZ (8%), and PB (1%).7 The result of
the 16 trials on a total of 1140 patients showed that PRM was
related to a moderate risk of GI complications. The small risk was
observed in VPA, CBZ, ethosuximide, felbamate, GBP and OXC. The
risk of GI complicationswas negligible in PHT, PB, LTG and TPM.8 In
line with our results, they showed that the probability of having GI
complications was higher in patients receiving GBP and CBZ than
those treating with PHT, PB and LTG.8
Our results revealed that 22.1% and 33.7% of patients treated
with single or multiple AEDs had vomiting and nausea, respec-
tively. Nausea and vomiting have been reported in patients
treating with CBZ, OXC, VPA, PHT, and TPM.9–12 However, the rate
of nausea and vomiting in these studies was less than our ﬁndings.
Herranz et al., in a study on 35 children treated with CBZ
monotherapy, found that 14% had GI disturbances including
nausea and vomiting.13 Nausea has been reported in 10.2% and
11.2% and vomiting was observed in 8.6% and 11.6% of the patients
treated with OXC or VPA, respectively.10 In another study, nausea
was reported in 13.2 and 15.5% and vomiting in 9.6 and 11.3% of
patients treated OXC and PHT, respectively.9 Bootsma et al.
reported that GI complaints including nausea, vomiting, and
stomachache was accounted for discontinuation of TPM treatment
in 10.1% of 470 epileptic patients.11
We observed diarrhea in 22.2% of our patients. The average drug
load of PHT was correlated to diarrhea in patients treated by
multiple AEDs in these patients. In line with our results, other
studies indicate a higher incidence of diarrhea accompanied by
PHT therapy.10,14 Constipation was also common among our
patients (27.3%). In one study, constipation reported in 5% and 1%of patients receiving VPA and placebo, respectively.15 Constipation
can also give rise to nausea and vomiting.14
Our ﬁndings revealed that CBZ, PHT, PB, VPA, LTG, OXC, and GBP
alone or in combination with other drugs can also cause heartburn
and dysphagia. To the best of our knowledge, no studies have
reported these complications in association with AEDs in epileptic
patients. We noted a signiﬁcant relationship between VPA therapy
and heartburn as well as a signiﬁcant correlation between GBP and
dysphagia. These complications may be related to long-term
therapy with AEDs in these patients. There are several general
mechanisms by which neurological side effects of AEDs can cause
or aggravate oropharyngeal dysphagia such as movement dis-
orders, myopathy, and disturbance of salivation.16 Dysphagia is a
frequent symptom in patients with many different neurological
disorders including brain trauma. The symptoms of neurogenic
dysphagia may be relatively inapparent due to a variety of factors.
A variety of medications including AEDs may cause or exacerbate
neurogenic dysphagia.16 However, in our patients dysphagia was
due to AEDs adverse effect and not caused by a CNS lesion as
withdrawal of the AEDs resolved the impairment in swallowing.
The most common prescribed drug for monotherapy was CBZ
and the most frequent drugs used in combination therapies were
PHT, CBZ, PB, and VPA. Some new AEDs (such as LTG and LEV) had
become available only very recently in Iran at the time of this
study. PHT was often prescribed with other AEDs in these patients.
PHT has drawbacks of a therapeutic window, considerable inter-
individual variation and non-linear saturable kinetics. PHT reduces
the blood levels of other AEDs such as CBZ, LTG, and VPA.17 These
interactions may potentially contribute to therapeutic failure of
AEDs in these patients.
Our study was limited to enrolling only men with post-
traumatic epilepsy, as well as small number of patients on
monotherapy. Considering the limitations to this study, larger
scale trials which include men and women and recruiting not only
post-traumatic epileptic patients, are warranted to investigate also
the GI side effects of AEDs.
5. Conclusion
Our ﬁndings revealed that GI complaints including nausea,
vomiting, diarrhea, constipation, heartburn, and dysphagia were
highly common in post-traumatic epileptic patients treated with
AEDs for a long-time. GI adverse effects can affect drug absorption
and utilization in epileptic patients resistant to drug therapy. This
may inﬂuence the efﬁcacy of drug therapy and increases the
probability of seizure attacks.
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